Soluble TRAIL in normal pregnancy and acute pyelonephritis: a potential explanation for the susceptibility of pregnant women to microbial products and infection

References

• Sacks G, Sargent I, Redman C. An innate view of human pregnancy. Immunol Today 1999;20:114–18
   PubMedGoogle Scholar
• Naccasha N, Gervasi MT, Chaiworapongsa T, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in normal pregnancy and maternal infection. Am J Obstet Gynecol 2001;185:1118–23
   PubMed Web of Science ®Google Scholar
• Chen X, Christou NV. Relative contribution of endothelial cell and polymorphonuclear neutrophil activation in their interactions in systemic inflammatory response syndrome. Arch Surg 1996;131:1148–53; discussion 1153–44
   PubMedGoogle Scholar
• Mori W. The Shwartzman reaction: a review including clinical manifestations and proposal for a univisceral or single organ third type. Histopathology 1981;5:113–26
   PubMed Web of Science ®Google Scholar
• Romero R, Gotsch F, Pineles B, Kusanovic JP. Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr Rev 2007;65:S194–202
   PubMed Web of Science ®Google Scholar
• Muller-Berghaus G, Schmidt-Ehry B. The role of pregnancy in the induction of the generalized Shwartzman reaction. Am J Obstet Gynecol 1972;114:847–49
   PubMed Web of Science ®Google Scholar
• Hankins GD, Whalley PJ. Acute urinary tract infections in pregnancy. Clin Obstet Gynecol 1985;28:266–78
   PubMed Web of Science ®Google Scholar
• Moritz AR, Weir D. Unilateral inhibition of the renal Shwartzman phenomenon following injection of bacterial filtrate into the renal artery. J Exp Med 1937;66:755–60
   PubMedGoogle Scholar
• Thomas L, Good RA. Studies on the generalized Shwartzman reaction: I. General observations concerning the phenomenon. J Exp Med 1952;96:605–24
   PubMedGoogle Scholar
• Haslett C, Savill JS, Meagher L. The neutrophil. Curr Opin Immunol 1989;2:10–18
   PubMed Web of Science ®Google Scholar
• Gervasi MT, Chaiworapongsa T, Naccasha N, et al. Maternal intravascular inflammation in preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2002;11:171–5
   PubMedGoogle Scholar
• Gervasi MT, Chaiworapongsa T, Naccasha N, et al. Phenotypic and metabolic characteristics of maternal monocytes and granulocytes in preterm labor with intact membranes. Am J Obstet Gynecol 2001;185:1124–9
   PubMed Web of Science ®Google Scholar
• Gervasi MT, Chaiworapongsa T, Pacora P, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol 2001;185:792–7
   PubMed Web of Science ®Google Scholar
• McGill SN, Ahmed NA, Hu F, et al. Shedding of L-selectin as a mechanism for reduced polymorphonuclear neutrophil exudation in patients with the systemic inflammatory response syndrome. Arch Surg 1996;131:1141–6; discussion 1147
   PubMed Web of Science ®Google Scholar
• Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998;179:80–6
   PubMed Web of Science ®Google Scholar
• Sabatier F, Bretelle F, D’Ercole C, et al. Neutrophil activation in preeclampsia and isolated intrauterine growth restriction. Am J Obstet Gynecol 2000;183:1558–63
   PubMed Web of Science ®Google Scholar
• Efrati P, Presentey B, Margalith M, Rozenszajn L. Leukocytes of normal pregnant women. Obstet Gynecol 1964;23:429–32
   PubMed Web of Science ®Google Scholar
• von Dadelszen P, Watson RW, Noorwali F, et al. Maternal neutrophil apoptosis in normal pregnancy, preeclampsia, and normotensive intrauterine growth restriction. Am J Obstet Gynecol 1999;181:408–14
   PubMed Web of Science ®Google Scholar
• Jimenez MF, Watson RW, Parodo J, et al. Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg 1997;132:1263–9; discussion 1269–70
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673–82
   PubMed Web of Science ®Google Scholar
• Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687–90
   PubMed Web of Science ®Google Scholar
• Renshaw SA, Parmar JS, Singleton V, et al. Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 2003;170:1027–33
   PubMed Web of Science ®Google Scholar
• Cziupka K, Busemann A, Partecke LI, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) improves the innate immune response and enhances survival in murine polymicrobial sepsis. Crit Care Med 2010;38:2169–74
   PubMed Web of Science ®Google Scholar
• McGrath EE, Marriott HM, Lawrie A, et al. TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation. J Leukoc Biol 2011;90:855–65
   PubMed Web of Science ®Google Scholar
• Chen L, Liu X, Zhu Y, et al. Localization and variation of TRAIL and its receptors in human placenta during gestation. Life Sci 2004;74:1479–86
   PubMed Web of Science ®Google Scholar
• Phillips TA, Ni J, Pan G, et al. TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege. J Immunol 1999;162:6053–9
   PubMed Web of Science ®Google Scholar
• Lonergan M, Aponso D, Marvin KW, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. J Clin Endocrinol Metab 2003;88:3835–44
   PubMed Web of Science ®Google Scholar
• Keogh RJ, Harris LK, Freeman A, et al. Fetal-derived trophoblast use the apoptotic cytokine tumor necrosis factor-alpha-related apoptosis-inducing ligand to induce smooth muscle cell death. Circ Res 2007;100:834–41
   PubMed Web of Science ®Google Scholar
• Whitley GS, Cartwright JE. Trophoblast-mediated spiral artery remodelling: a role for apoptosis. J Anat 2009;215:21–6
   PubMed Web of Science ®Google Scholar
• Agostinis C, Bulla R, Tisato V, et al. Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells. Hum Reprod 2012;27:2941–7
   PubMed Web of Science ®Google Scholar
• Soto E, Romero R, Vaisbuch E, et al. Fragment Bb: evidence for activation of the alternative pathway of the complement system in pregnant women with acute pyelonephritis. J Matern Fetal Neonatal Med 2010;23:1085–90
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Gotsch F, et al. Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma. J Matern Fetal Neonatal Med 2010;23:167–78
   PubMed Web of Science ®Google Scholar
• Gotsch F, Romero R, Espinoza J, et al. Maternal serum concentrations of the chemokine CXCL10/IP-10 are elevated in acute pyelonephritis during pregnancy. J Matern Fetal Neonatal Med 2007;20:735–44
   PubMed Web of Science ®Google Scholar
• Soto E, Richani K, Romero R, et al. Increased concentration of the complement split product C5a in acute pyelonephritis during pregnancy. J Matern Fetal Neonatal Med 2005;17:247–52
   PubMed Web of Science ®Google Scholar
• Kusanovic JP, Romero R, Esoinoza J, et al. Maternal serum soluble CD30 is increased in pregnancies complicated with acute pyelonephritis. J Matern Fetal Neonatal Med 2007;20:803–11
   PubMed Web of Science ®Google Scholar
• Jolley JA, Kim S, Wing DA. Acute pyelonephritis and associated complications during pregnancy in 2006 in US hospitals. J Matern Fetal Neonatal Med 2012;25:2494--8
   Google Scholar
• Cunningham FG, Leveno KJ, Hankins GD, Whalley PJ. Respiratory insufficiency associated with pyelonephritis during pregnancy. Obstet Gynecol 1984;63:121–5
   PubMed Web of Science ®Google Scholar
• Amstey MS. Frequency of adult respiratory distress syndrome in pregnant women who have pyelonephritis. Clin Infect Dis 1992;14:1260–1
   PubMed Web of Science ®Google Scholar
• Catanzarite VA, Willms D. Adult respiratory distress syndrome in pregnancy: report of three cases and review of the literature. Obstet Gynecol Surv 1997;52:381–92
   PubMedGoogle Scholar
• Cunningham FG, Lucas MJ, Hankins GD. Pulmonary injury complicating antepartum pyelonephritis. Am J Obstet Gynecol 1987;156:797–807
   PubMed Web of Science ®Google Scholar
• Pruett K, Faro S. Pyelonephritis associated with respiratory distress. Obstet Gynecol 1987;69:444–6
   PubMed Web of Science ®Google Scholar
• Cunningham FG, Lucas MJ. Urinary tract infections complicating pregnancy. Baillieres Clin Obstet Gynaecol 1994;8:353–73
   PubMed Web of Science ®Google Scholar
• Elkington KW, Greb LC. Adult respiratory distress syndrome as a complication of acute pyelonephritis during pregnancy: case report and discussion. Obstet Gynecol 1986;67:18S–20S
   PubMed Web of Science ®Google Scholar
• Soisson AP, Eldridge E, Kopelman JN, Duff P. Acute pyelonephritis complicated by respiratory insufficiency. A case report. J Reprod Med 1986;31:525–7
   PubMed Web of Science ®Google Scholar
• Towers CV, Kaminskas CM, Garite TJ, et al. Pulmonary injury associated with antepartum pyelonephritis: can patients at risk be identified? Am J Obstet Gynecol 1991;164:974–8; discussion 978–80
   PubMed Web of Science ®Google Scholar
• Yazigi R, Lerner S, Tejani N. Association of acute pyelonephritis with pulmonary complications in pregnancy. A report of two cases. J Reprod Med 1990;35:562–4
   PubMed Web of Science ®Google Scholar
• Bubeck RW. Acute pyelonephritis during pregnancy with anuria, septicemia and thrombocytopenia. Del Med J 1968;40:143–7
   PubMedGoogle Scholar
• Cunningham FG, Morris GB, Mickal A. Acute pyelonephritis of pregnancy: a clinical review. Obstet Gynecol 1973;42:112–17
   PubMed Web of Science ®Google Scholar
• Snyder CC, Barton JR, Habli M, Sibai BM. Severe sepsis and septic shock in pregnancy: indications for delivery and maternal and perinatal outcomes. J Matern Fetal Neonatal Med 2013;26:503--6
   Google Scholar
• Gilstrap LC 3rd, Cunningham FG, Whalley PJ. Acute pyelonephritis in pregnancy: an anterospective study. Obstet Gynecol 1981;57:409–13
   PubMed Web of Science ®Google Scholar
• Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007;39:1462–75
   PubMed Web of Science ®Google Scholar
• Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004;201:331–40
   PubMed Web of Science ®Google Scholar
• Bodmer JL, Holler N, Reynard S, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000;2:241–3
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12:611–20
   PubMed Web of Science ®Google Scholar
• Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000;12:599–609
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995;14:5579–88
   PubMed Web of Science ®Google Scholar
• Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997;7:831–6
   PubMed Web of Science ®Google Scholar
• Rossi D, Gaidano G. Messengers of cell death: apoptotic signaling in health and disease. Haematologica 2003;88:212–8
   PubMed Web of Science ®Google Scholar
• Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815–18
   PubMed Web of Science ®Google Scholar
• Schneider P, Bodmer JL, Thome M, et al. Characterization of two receptors for TRAIL. FEBS Lett 1997;416:329–34
   PubMed Web of Science ®Google Scholar
• Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818–21
   PubMed Web of Science ®Google Scholar
• Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186:1165–70
   PubMed Web of Science ®Google Scholar
• Marsters SA, Sheridan JP, Pitti RM, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997;7:1003–6
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–19
   PubMed Web of Science ®Google Scholar
• Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363–7
   PubMed Web of Science ®Google Scholar
• Chaudhary PM, Eby M, Jasmin A, et al. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997;7:821–30
   PubMed Web of Science ®Google Scholar
• Wajant H, Moosmayer D, Wuest T, et al. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001;20:4101–6
   PubMedGoogle Scholar
• Tecchio C, Huber V, Scapini P, et al. IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004;103:3837–44
   PubMed Web of Science ®Google Scholar
• Secchiero P, Gonelli A, Carnevale E, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003;107:2250–6
   PubMed Web of Science ®Google Scholar
• Daniels RA, Turley H, Kimberley FC, et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 2005;15:430–8
   PubMed Web of Science ®Google Scholar
• Zhang XD, Nguyen T, Thomas WD, et al. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000;482:193–9
   PubMed Web of Science ®Google Scholar
• Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 2009;625:63–72
   PubMed Web of Science ®Google Scholar
• Zauli G, Bosco R, Secchiero P. Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opin Ther Targets 2011;15:931–42
   PubMed Web of Science ®Google Scholar
• Lin Y, Devin A, Cook A, et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol 2000;20:6638–45
   PubMed Web of Science ®Google Scholar
• Collison A, Foster PS, Mattes J. Emerging role of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as a key regulator of inflammatory responses. Clin Exp Pharmacol Physiol 2009;36:1049–53
   PubMed Web of Science ®Google Scholar
• Milani D, Zauli G, Rimondi E, et al. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 2003;86:126–35
   PubMedGoogle Scholar
• Muhlenbeck F, Haas E, Schwenzer R, et al. TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways. J Biol Chem 1998;273:33091–8
   PubMed Web of Science ®Google Scholar
• Yerbes R, Palacios C, Lopez-Rivas A. The therapeutic potential of TRAIL receptor signalling in cancer cells. Clin Transl Oncol 2011;13:839–47
   PubMed Web of Science ®Google Scholar
• Cretney E, Takeda K, Yagita H, et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002;168:1356–61
   PubMed Web of Science ®Google Scholar
• Sedger LM, Glaccum MB, Schuh JC, et al. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 2002;32:2246–54
   PubMed Web of Science ®Google Scholar
• Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, et al. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol 2003;4:255–60
   PubMed Web of Science ®Google Scholar
• Azab NA, Rady HM, Marzouk SA. Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement. Clin Rheumatol 2012;31:1359--64
   Google Scholar
• Mori K, Ikari Y, Jono S, et al. Association of serum TRAIL level with coronary artery disease. Thromb Res 2010;125:322–5
   PubMed Web of Science ®Google Scholar
• Bisgin A, Kargi A, Yalcin AD, et al. Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. BMC Cancer 2012;12:1--5
   PubMedGoogle Scholar
• Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:854–8
   PubMedGoogle Scholar
• Audo R, Calmon-Hamaty F, Baeten D, et al. Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. Arthritis Rheum 2011;63:904–13
   PubMedGoogle Scholar
• Herbeuval JP, Boasso A, Grivel JC, et al. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 2005;105:2458–64
   PubMed Web of Science ®Google Scholar
• Deftereos S, Giannopoulos G, Kossyvakis C, et al. Association of soluble tumour necrosis factor-related apoptosis-inducing ligand levels with coronary plaque burden and composition. Heart 2012;98:214–8
   PubMed Web of Science ®Google Scholar
• Volpato S, Ferrucci L, Secchiero P, et al. Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 2011;215:452–8
   PubMed Web of Science ®Google Scholar
• Bai X, Williams JL, Greenwood SL, et al. A placental protective role for trophoblast-derived TNF-related apoptosis-inducing ligand (TRAIL). Placenta 2009;30:855–60
   PubMed Web of Science ®Google Scholar
• Zauli G, Monasta L, Rimondi E, et al. Circulating TRAIL shows a significant post-partum decline associated to stressful conditions. PLoS One 2011;6:e27011--9
   PubMedGoogle Scholar
• Kayagaki N, Yamaguchi N, Nakayama M, et al. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 1999;162:2639–47
   PubMed Web of Science ®Google Scholar
• Kaplan MJ, Ray D, Mo RR, et al. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol 2000;164:2897–904
   PubMed Web of Science ®Google Scholar
• Wallin RP, Screpanti V, Michaelsson J, et al. Regulation of perforin-independent NK cell-mediated cytotoxicity. Eur J Immunol 2003;33:2727–35
   PubMed Web of Science ®Google Scholar
• Zhu DM, Shi J, Liu S, et al. HIV infection enhances TRAIL-induced cell death in macrophage by down-regulating decoy receptor expression and generation of reactive oxygen species. PLoS One 2011;6:e18291--9
   PubMedGoogle Scholar
• Miura Y, Misawa N, Maeda N, et al. Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice. J Exp Med 2001;193:651–60
   PubMedGoogle Scholar
• Andrews JI, Griffith TS, Meier JL. Cytomegalovirus and the role of interferon in the expression of tumor necrosis factor-related apoptosis-inducing ligand in the placenta. Am J Obstet Gynecol 2007;197:608 e601–6
   Google Scholar
• Brincks EL, Katewa A, Kucaba TA, et al. CD8 T cells utilize TRAIL to control influenza virus infection. J Immunol 2008;181:4918–25
   PubMedGoogle Scholar
• Herold S, Steinmueller M, von Wulffen W, et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med 2008;205:3065–77
   PubMed Web of Science ®Google Scholar
• Clarke P, Meintzer SM, Gibson S, et al. Reovirus-induced apoptosis is mediated by TRAIL. J Virol 2000;74:8135–9
   PubMed Web of Science ®Google Scholar
• Bem RA, Bos AP, Wosten-van Asperen RM, et al. Potential role of soluble TRAIL in epithelial injury in children with severe RSV infection. Am J Respir Cell Mol Biol 2010;42:697–705
   PubMed Web of Science ®Google Scholar
• Gurung P, Rai D, Condotta SA, et al. Immune unresponsiveness to secondary heterologous bacterial infection after sepsis induction is TRAIL dependent. J Immunol 2011;187:2148–54
   PubMedGoogle Scholar
• Steinwede K, Henken S, Bohling J, et al. TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. J Exp Med 2012;209:1937–52
   PubMedGoogle Scholar
• Hoffmann O, Priller J, Prozorovski T, et al. TRAIL limits excessive host immune responses in bacterial meningitis. J Clin Invest 2007;117:2004–13
   PubMedGoogle Scholar